pde4 in 4

PDE4-IN-4 is a compound acting as both a potent M3 antagonist (p IC 50 = 10.2) and a PDE4 inhibitor (p IC 50 = 8.8), designed for inhalation-based treatment of pulmonary diseases.

ethyl 1-(4-aminophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate 又称 EAPT，是一种有效的选择性 PDE4抑制剂，调节细胞内环腺苷酸(cAMP)水平。它已被用于多种科研应用，包括 cAMP 介导的信号转导通路的研究，并有潜力作为治疗炎症和免疫相关疾病的药物。

PDE4 inhibitor intermediate 1 is a PDE4 inhibitor synthesis intermediate.

M3 PDE4 modulator-1 (10f) 为多功能化合物，具备M3mAChR拮抗和PDE4抑制作用。于OVA大鼠模型中，M3 PDE4 modulator-1 (10-1000 nM kg；iv) 能降低半胱氨酸嗜酸性粒细胞内流。

PDE IV-IN-1 是一种有效的磷酸二酯酶4 (PDE4)抑制剂，具有抗炎活性，可用于治疗哮喘，慢性阻塞性肺病和其他炎症性疾病，是研究抑郁症的潜在化合物。

Oglemilast (GRC 3886) 是一种具有口服活性磷酸二酯酶 4 (PDE4) 抑制剂，对 PDE4D3 的 IC50 为 0.5 nM。Oglemilast 在体外和体内抑制肺细胞浸润，包括嗜酸性粒细胞增多和嗜中性粒细胞减少。Oglemilast 具有应用于炎症性气道疾病的潜力。

AWD 12-281 是一种选择性磷酸二酯酶 4 (PDE4) 抑制剂，具有抗炎活性和支气管扩张活性，用于研究慢性阻塞性肺疾病（COPD）。

PF-07038124 HCl 是一种具有选择性和高效性的 PDE4 抑制剂，对 PDE4B2 的 IC50 为0.5 nM。PF-07038124 HCl 抑制 IL-13、IL-4 和 IFNγ，可用于研究特应性皮炎和斑块状银屑病等皮肤疾病。

Dovramilast (CC-11050) 是一种具有口服活性的磷酸二酯酶4(PDE4)抑制剂，，可以减少促炎介质和细胞因子的产生。Dovramilast 可用于研究结核分枝杆菌感染和红斑狼疮。

(S)-(+)-Rolipram ((+)-Rolipram) 是一种 cAMP 依赖性磷酸二酯酶 4 (PDE4) 抑制剂，IC50=1100 nM。它能够抑制人单核细胞产生的肿瘤坏死因子 α (TNFα)。

PDE4-IN-22 (Compound 2e) 为一种PDE4抑制剂，IC50 测定值仅为2.4 nM。该化合物展示出了抗炎效果，并在Imiquimod 诱导的银屑病小鼠模型中显示出强大的治疗潜力，有效抑制银屑病症状。

GPD-1116 是一种口服活性的PDE4和PDE1磷酸二酯酶抑制剂，能有效减少烟雾导致的肺细胞凋亡。此化合物在多种动物疾病模型中显示出疗效，如肺气肿、急性肺损伤、慢性阻塞性肺病 (COPD)、哮喘及肺动脉高压。

Eggmanone (EGM1) 是一种有效的、选择性的磷酸二酯酶 4(PDE4)拮抗剂，对 PDE4D3 的 IC50为 72 nM。Eggmanone 对 PDE4D3 的选择性大约是其他 PDE 的 40-50 倍。Eggmanone 通过选择性拮抗 PDE4 发挥 Hh 抑制作用，导致蛋白激酶 A 激活和随后的 Hh 阻断。

O-Demethyl apremilast is an active metabolite of the phosphodiesterase 4 (PDE4) inhibitor apremilast .1It inhibits the activity of PDE4 isolated from U937 cells and LPS-induced TNF-α production in isolated human peripheral blood mononuclear cells (PBMCs; IC50s = 8.3 and 5.6 μM, respectively). O-Demethyl apremilast is also an oxidative degradation product of apremilast.2,3 1.Hoffmann, M., Kumar, G., Schafer, P., et al.Disposition, metabolism and mass balance of [14C]apremilast following oral administrationXenobiotica41(12)1063-1075(2011) 2.Lu, Y., Shen, X., Hang, T., et al.Identification and characterization of process-related substances and degradation products in apremilast: Process optimization and degradation pathway elucidationJ. Pharm. Biomed. Anal.14170-78(2017) 3.Bhole, R.P., Naksakhare, S.R., and Bonde, C.G.A stability indicating HPTLC method for apremilast and identification of degradation products using MS MSJ. Pharm. Sci. & Res.11(5)1861-1869(2019)

LEO 39652 is a dual-soft PDE4 inhibitor with IC50s of 1.2 nM, 1.2 nM, 3.0 nM and 3.8 nM for PDE4A, PDE4B, PDE4C and PDE4D, respectively. LEO 39652 also inhibits TNF-α with an IC50 value of 6.0 nM. LEO 39652 is used for topical research of Atopic dermatitis (AD) [1]. LEO 39652 shows unbound in vitro potency when measured as LPS induced TNF-α release in human peripheral blood mononuclear cells (PBMC), incubated in serum free medium. LEO 39652 shows a relatively high binding to human serum albumin[2]. LEO 39652 is inactivated both in blood and liver (dual-soft) while stabled in the skin[1].Pharmacokinetic AnalysisLEO 39652 exhibits total clearance (rats 930, minipigs 200 and monkey 300 mL min kg) and ratio to total AUC (rats 4, minipigs 6 and monkey 6 %) following intravenous administration (rats 0.075, minipigs 0.5 and monkeys 2.0 mg kg)[1]. [1]. Jens Larsen, et al. Discovery and Early Clinical Development of Isobutyl 1-[8-Methoxy-5-(1-oxo-3 H-isobenzofuran-5-yl)-[1,2,4]triazolo[1,5- a]pyridin-2-yl]cyclopropanecarboxylate (LEO 39652), a Novel Dual-Soft PDE4 Inhibitor for Topical Treatment of Atopic Dermatitis. J Med Chem. 2020 Dec 10;63(23):14502-14521.[2]. Stefan Eirefelt

Tetomilast (OPC-6535) is a phosphodiesterase-4 (PDE4) inhibitor, potentially effective in treating inflammatory bowel disease (IBD) and chronic obstructive pulmonary disease (COPD).

PDE4-IN-3 is a newly developed oral compound that acts as a potent inhibitor of the enzyme phosphodiesterase 4 (PDE4), displaying a high affinity for inhibition with an IC50 value of 4.2 nM.

PDE4-IN-8 (Example 5) 是磷酸二酯酶4(PDE4)的有效抑制剂。PDE4-IN-8 对 PDE4B2 的 IC50值为 0.93 nM。然而，PDE4-IN-8 对 IL13、IL4、IFNy 的抑制作用微弱，IC50值分别为 4.04 nM, 36.33 nM, 2394 nM。

PDE4-IN-11 is a potent phosphodiesterase isoenzyme 4 (PDE4) inhibitor, exhibiting remarkable bronchodilatory and anti-inflammatory characteristics. It is specifically designed for studying obstructive or inflammatory airway diseases [1] [2] [3].

AWD 12-281 is a selective phosphodiesterase 4 (PDE4) inhibitor for the treatment of lung inflammation using inhalative administration. AWD 12-281 Is Active in a New Guinea-Pig Model of Allergic Skin Inflammation Predictive of Human Skin Penetration and Suppresses Both Th1 and Th2 Cytokines in Mice. AWD 12-281 is a very promising drug candidate not only for the treatment of lung inflammation using inhalative administration but also for the treatment of atopic dermatitis.

Fenspiride-d5 is intended for use as an internal standard for the quantification of fenspiride by GC- or LC-MS. Fenspiride is an antagonist of histamine H1 receptors and a non-steroidal anti-inflammatory drug (NSAID). It inhibits histamine-induced contraction of isolated guinea pig trachea but not histamine-induced inotropy of isolated guinea pig heart. It also inhibits phosphodiesterase 4 (PDE4), PDE5, and PDE3 (IC50s = 69, ~158, and 363 µM, respectively, in isolated human bronchi derived from patients with lung cancer). It is selective for these phosphodiesterases over PDE1 and PDE2, where it provides less than 25% inhibition. Fenspiride potentiates the airway relaxant effects of isoproterenol and sodium nitroprusside indicating an effect on cAMP and cGMP phosphodiesterases, respectively. Aerosolized fenspiride (1 mg ml) reverses bronchoconstriction induced by capsaicin and, when used at aerosolized concentrations ranging from 1-10 mg ml, reduces cough induced by citric aci......

LEO-29102 is a potent, selective, and soft-drug phosphodiesterase 4 (PDE4) inhibitor, which may be potentially useful for treatment of dermatological diseases. LEO 29102 shows properties suitable for patient-friendly formulations giving efficient drug delivery to the skin. LEO-29102 has reached phase 2 and demonstrated clinically relevant efficacy in the treatment of atopic dermatitis.

Toddacoumalone 是一种天然PDE4 (磷酸二酯酶 4) 抑制剂，效力中等，活性分子特性不完善。具有研究银屑病等炎症性疾病潜力。

PDE4-IN-13 is a phosphodiesterase 4 inhibitor with an IC50 value of 1.56 μM, exhibiting anti-inflammatory and antioxidative properties. It is utilized in the study of chronic obstructive pulmonary disease (COPD).